- Home
- CHRS vs RMAX Comparison
CHRS vs RMAX Comparison
Compare CHRS & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- RMAX
- Stock Information
- Founded
- CHRS 2010
- RMAX 1973
- Country
- CHRS United States
- RMAX United States
- Employees
- CHRS N/A
- RMAX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- RMAX Real Estate
- Sector
- CHRS Health Care
- RMAX Finance
- Exchange
- CHRS Nasdaq
- RMAX Nasdaq
- Market Cap
- CHRS 159.2M
- RMAX 178.3M
- IPO Year
- CHRS 2014
- RMAX 2013
- Fundamental
- Price
- CHRS $1.35
- RMAX $9.92
- Analyst Decision
- CHRS Strong Buy
- RMAX Hold
- Analyst Count
- CHRS 4
- RMAX 1
- Target Price
- CHRS $4.51
- RMAX $9.00
- AVG Volume (30 Days)
- CHRS 1.2M
- RMAX 212.6K
- Earning Date
- CHRS 11-05-2025
- RMAX 10-30-2025
- Dividend Yield
- CHRS N/A
- RMAX N/A
- EPS Growth
- CHRS N/A
- RMAX N/A
- EPS
- CHRS 1.55
- RMAX 0.48
- Revenue
- CHRS $272,209,000.00
- RMAX $298,162,000.00
- Revenue This Year
- CHRS N/A
- RMAX N/A
- Revenue Next Year
- CHRS $109.48
- RMAX N/A
- P/E Ratio
- CHRS $0.87
- RMAX $20.66
- Revenue Growth
- CHRS 52.33
- RMAX N/A
- 52 Week Low
- CHRS $0.66
- RMAX $6.90
- 52 Week High
- CHRS $2.43
- RMAX $14.31
- Technical
- Relative Strength Index (RSI)
- CHRS 64.99
- RMAX 63.07
- Support Level
- CHRS $1.23
- RMAX $9.64
- Resistance Level
- CHRS $1.40
- RMAX $9.92
- Average True Range (ATR)
- CHRS 0.08
- RMAX 0.31
- MACD
- CHRS -0.00
- RMAX 0.02
- Stochastic Oscillator
- CHRS 72.13
- RMAX 70.80
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.